ClinicalTrials.gg
RecruitingNCT07209111KANDLELIT-014Updated Nov 2, 2026

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

A Phase 2 interventional study of Calderasib and Cetuximab in Neoplasm Malignant, sponsored by Merck Sharp & Dohme LLC. Recruiting at 72 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 2, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation.

The goals of this study are to learn:

  • How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare
  • About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
02

Conditions studied

  • Neoplasm Malignant

Browse trials for

Keywords

  • KRAS
  • NSCLC
  • CRC
  • Tumor-agnostic
  • Pan Tumor
  • KRAS G12C
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 150 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced unresectable or solid tumor other than colorectal cancer and has progressed on, or following, standard of care systemic treatment
  • Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system and/or carcinomatous meningitis and/or primary brain tumors
  • Has active infection, other than those permitted per protocol, requiring systemic therapy
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Calderasib

    Participants will receive calderasib orally. Per protocol treatment of calderasib has no maximum number of cycles. Participants will be treated until any of the criteria for discontinuation of study intervention are met.

    Drug: Calderasib

  • Experimental
    Calderasib + Cetuximab

    Participants will receive calderasib orally. Participants will receive Cetuximab 500 mg/m\^2 via intravenous (IV) infusion once every 2 weeks (Q2W). Per protocol treatment of calderasib and Cetuximab has no maximum number of cycles. Participants will be treated until any of the criteria for discontinuation of study intervention are met.

    Drug: Calderasib · Biological: Cetuximab

Interventions

  • Oral administration

    Also known as: MK-1084

  • BiologicalCetuximab

    Intravenous administration

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 76 months

  2. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 76 months

  3. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 76 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to approximately 76 months

  2. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 76 months

  3. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death due to any cause. OS will be presented.

    Time frame: Up to approximately 76 months

07

Study locations

71 of 72 sites recruiting
  • Greater Baltimore Medical Center ( Site 1104)
    Baltimore, Maryland 21204, United States
    Recruiting
    • Study Coordinator · Contact443-849-3285
  • START Midwest ( Site 1103)
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Study Coordinator · Contact616-389-1808
  • Comprehensive Cancer Centers of Nevada ( Site 1109)
    Las Vegas, Nevada 89169, United States
    Recruiting
    • Study Coordinator · Contact702-952-3400
  • Rutgers Cancer Institute of New Jersey ( Site 1100)
    New Brunswick, New Jersey 08903, United States
    Recruiting
    • Study Coordinator · Contact732-235-3443
  • START Mountain Region ( Site 1106)
    West Valley City, Utah 84119, United States
    Recruiting
    • Study Coordinator · Contact210-593-5250
  • Virginia Cancer Specialists ( Site 1102)
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact703-208-9268
  • Prince of Wales Hospital-Medical Oncology ( Site 1003)
    Randwick, New South Wales 2031, Australia
    Recruiting
    • Study Coordinator · Contact+61293825131
  • Westmead Hospital ( Site 1000)
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Study Coordinator · Contact+61411462609
  • Epworth Freemasons ( Site 1004)
    Melbourne, Victoria 3002, Australia
    Recruiting
    • Study Coordinator · Contact+6194268880
  • The Ottawa Hospital ( Site 2902)
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Study Coordinator · Contact613-737-7700
  • Jewish General Hospital-CRU ( Site 2900)
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
    • Study Coordinator · Contact514-340-8222
  • Fundación Arturo López Pérez ( Site 1200)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56224457398
  • Centro de Oncología de Precisión ( Site 1202)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact+56225189885
  • Clinica San Carlos de Apoquindo ( Site 1203)
    Santiago, Region M. de Santiago 7620002, Chile
    Recruiting
    • Study Coordinator · Contact56934331806
  • Bradfordhill ( Site 1201)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • Beijing Cancer hospital ( Site 1318)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact010-88121122
  • The First Affiliated Hospital of Xiamen University ( Site 1304)
    Xiamen, Fujian 361003, China
    Recruiting
    • Study Coordinator · Contact+8613860458889
  • Sun Yat-sen University Cancer Center ( Site 1303)
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Study Coordinator · Contact020-87343105
  • The first affiliated hospital, Sun Yat-Sen university ( Site 1329)
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Study Coordinator · Contact020-87755766
  • Harbin Medical University Cancer Hospital ( Site 1308)
    Harbin, Heilongjiang 150000, China
    Recruiting
    • Study Coordinator · Contact0451 8629 8666
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1326)
    Wuhan, Hubei 430000, China
    Recruiting
    • Study Coordinator · Contact+86 027 83262682
  • Hunan Cancer Hospital ( Site 1321)
    Changsha, Hunan 410013, China
    Recruiting
    • Study Coordinator · Contact0731-89762321
  • Hunan Cancer Hospital ( Site 1322)
    Changsha, Hunan 410013, China
    Recruiting
    • Study Coordinator · Contact0731-89762321
  • Jiangsu Province Hospital ( Site 1324)
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Study Coordinator · Contact+8602583718836
  • The First Affiliated Hospital of Nanchang University ( Site 1307)
    Nanchang, Jiangxi 330209, China
    Recruiting
    • Study Coordinator · Contact86079188695051
  • Jinan Central Hospital ( Site 1313)
    Jinan, Shandong 250013, China
    Recruiting
    • Study Coordinator · Contact0531-5586500
  • Shanghai Chest Hospital ( Site 1300)
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • Study Coordinator · Contact021-22200000
  • Fudan University Shanghai Cancer Center ( Site 1325)
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Study Coordinator · Contact021-64175590
  • Zhongshan Hospital,Fudan University ( Site 1301)
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Study Coordinator · Contact021-64041990
  • Zhejiang Cancer Hospital ( Site 1311)
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Study Coordinator · Contact0571-88122222
  • Taizhou Hospital of Zhejiang Province ( Site 1312)
    Linhai, Zhejiang 317000, China
    Recruiting
    • Study Coordinator · Contact0576-85199810
  • Rigshospitalet ( Site 1403)
    Copenhagen, Capital Region 2100, Denmark
    Recruiting
    • Study Coordinator · Contact+45 35455072
  • Odense Universitetshospital ( Site 1401)
    Odense, Region Syddanmark 5000, Denmark
    Recruiting
    • Study Coordinator · Contact+45 2963 1327
  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1503)
    Limoges, Haute-Vienne 87042, France
    Recruiting
    • Study Coordinator · Contact+33555087292
  • Hopital Pitie Salpetriere ( Site 1500)
    Paris, 75013, France
    Recruiting
    • Study Coordinator · Contact+33184827695
  • Universitätsklinikum Leipzig ( Site 1602)
    Leipzig, Saxony 04103, Germany
    Recruiting
    • Study Coordinator · Contact+493419712560
  • Universitätsklinikum Jena ( Site 1603)
    Jena, Thuringia 07747, Germany
    Recruiting
    • Study Coordinator · Contact+4936419324584
  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1604)
    Berlin, 10117, Germany
    Recruiting
    • Study Coordinator · Contact+4930450577041
  • General Hospital of Athens "Laiko" ( Site 1701)
    Athens, Attica 11527, Greece
    Recruiting
    • Study Coordinator · Contact+302132060954
  • European Interbalkan Medical Center-Oncology Department ( Site 1700)
    Thessaloniki, 57001, Greece
    Recruiting
    • Study Coordinator · Contact+302310400213
  • Emek Medical Center ( Site 1800)
    Afula, 1834111, Israel
    Recruiting
    • Study Coordinator · Contact+97246495389
  • Hadassah Medical Center ( Site 1801)
    Jerusalem, 9112001, Israel
    Recruiting
    • Study Coordinator · Contact+97226777333
  • Sourasky Medical Center ( Site 1802)
    Tel Aviv, 6423906, Israel
    Recruiting
    • Study Coordinator · Contact+97236974444
  • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1902)
    Rozzano, Milano 20089, Italy
    Recruiting
    • Study Coordinator · Contact+390282244559
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1900)
    Milan, 20133, Italy
    Recruiting
    • Study Coordinator · Contact00390223903210
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1901)
    Roma, 00168, Italy
    Recruiting
    • Study Coordinator · Contact00390630155202
  • National Cancer Center Hospital East ( Site 2001)
    Kashiwa, Chiba 277-8577, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kanagawa Cancer Center ( Site 2002)
    Yokohama, Kanagawa 241-8515, Japan
    Recruiting
    • Study Coordinator · Contact+81-45-520-2222
  • National Cancer Center Hospital ( Site 2000)
    Chūō, Tokyo 104-0045, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3542-2511
  • Cancer Institute Hospital of JFCR ( Site 2003)
    Koto, Tokyo 135-8550, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3520-0111
  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 2004)
    Osaka, 541-8567, Japan
    Recruiting
    • Study Coordinator · Contact+81-6-6945-1181
  • Haukeland universitetssykehus ( Site 2102)
    Bergen, Hordaland 5021, Norway
    Recruiting
    • Study Coordinator · Contact+4755972890
  • Oslo universitetssykehus, Radiumhospitalet ( Site 2101)
    Oslo, 0379, Norway
    Recruiting
    • Study Coordinator · Contact+4723026600
  • MTZ Clinical Research powered by Pratia ( Site 2205)
    Warsaw, Masovian Voivodeship 02-172, Poland
    Recruiting
    • Study Coordinator · Contact+48225725959
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2200)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact+48225463384
  • Szpital Wojewodzki im. Mikolaja Kopernika w Koszalinie ( Site 2203)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
    Recruiting
    • Study Coordinator · Contact+48509098854
  • Seoul National University Hospital ( Site 2301)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact82-2-2072-1525
  • Asan Medical Center ( Site 2302)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230101720
  • Samsung Medical Center ( Site 2300)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234103459
  • Hospital Virgen de la Victoria ( Site 2403)
    Málaga, Malaga 29010, Spain
    Recruiting
    • Study Coordinator · Contact0034 671 594 566
  • Hospital Universitari Vall d Hebron ( Site 2401)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34932746000
  • Hospital Clinic de Barcelona ( Site 2402)
    Barcelona, 08036, Spain
    Recruiting
    • Study Coordinator · Contact+34932274208
  • Hospital Clinico San Carlos ( Site 2404)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact+34913303000
  • Karolinska Universitetssjukhuset Solna ( Site 2501)
    Stockholm, Stockholm County 171 64, Sweden
    Recruiting
    • Study Coordinator · Contact+4612373816
  • Sahlgrenska Universitetssjukhuset. ( Site 2502)
    Gothenburg, Västra Götaland County 413 45, Sweden
    Recruiting
    • Study Coordinator · Contact+46313421000
  • Adana Medical Park Seyhan Hastanesi ( Site 2706)
    Adana, 01140, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact00904444484
  • Gazi Universitesi Tip Fakultesi Hastanesi ( Site 2702)
    Ankara, 06560, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+9003122024000
  • Ankara Bilkent Şehir Hastanesi ( Site 2701)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90312 552 60 00
  • Hacettepe Universitesi-oncology hospital ( Site 2700)
    Ankara, 6230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903123054330
  • Koc University Hospital ( Site 2704)
    Istanbul, 34010, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+908502508250
  • Royal Free Hospital ( Site 2801)
    London, Camden NW3 2QG, United Kingdom
    Recruiting
    • Study Coordinator · Contact+4402077940500
  • The Christie NHS Foundation Trust ( Site 2803)
    Manchester, M20 4BX, United Kingdom
    Recruiting
    • Study Coordinator · Contact01614463466
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2032, 76 months after the start.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 76 months is above that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 6, 2025
StartActual
Dec 4, 2025
Primary completionEst.
Apr 9, 2032
CompletionEst.
Apr 9, 2032
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. National Cancer Center Hospital East ( Site 2001) is now Active, not recruiting
Show 2 added (1 Chile, 1 Japan)
  • Fundación Arturo López Pérez ( Site 1200) · Santiago, Chile
  • National Cancer Center Hospital East ( Site 2001) · Kashiwa, Japan
Show 1 removed
  • FALP ( Site 1200) · Santiago, Chile
across 3 updates, Oct 1, 2026 – Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Cancer Center Hospital East ( Site 2001) · Kashiwa, JapanContact removed •••1111
Nov 2, 2026
Show all 3 updates
  1. Nov 2, 2026
    National Cancer Center Hospital East ( Site 2001) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Cancer Center Hospital East ( Site 2001) · Kashiwa, JapanContact removed •••1111
    + 1 other change: references
  2. Oct 7, 2026
    1 site added
    Show site
    • National Cancer Center Hospital East ( Site 2001) · Kashiwa, Japan
    + 1 other change: verification date
  3. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Fundación Arturo López Pérez ( Site 1200) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 1200) · Santiago, Chile
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07209111
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Dec 4, 2025
Primary completion
Apr 9, 2032 (estimated)
Completion
Apr 9, 2032 (estimated)
Last update
Nov 2, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calderasib

Start the discussion